LGNDLigand Pharmaceuticals, Inc. - Ordinary Shares - Class B
$274.88
$11.74
(4.46%)
Closed $274.88
$0.0028
(0.00%)
After Hours
EarningsAug 6
Mkt Cap$5.51B
Vol609,561.00
Fundamentals
Ligand Pharmaceuticals Reaches Analyst Target Price
In recent trading, shares of Ligand Pharmaceuticals Inc (Symbol: LGND) have crossed above the average analyst 12-month target price of $271.00, changing hands for $274.88/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: down...
Nasdaq News: Markets
Ligand Pharmaceuticals Director Unloads 2,501 Shares Should You Be Concerned?
Key PointsKozarich sold 2,501 common shares...
Nasdaq News: Markets
A Ligand Pharmaceuticals (LGND) Insider Sold 5,000 Shares for $1.1 Million
Key Points5,000 shares were sold for a total transaction value of ~$1.14 million on June 1, 2026, at a weighted average price around $227.06 per share...
Nasdaq News: Markets
Insider Selling: Ligand Pharmaceuticals (NASDAQ:LGND) Insider Sells 5,000 Shares of Stock
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Get Free Report) insider Andrew Reardon sold 5,000 shares of the business's stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $231.31, for a total transaction of $1,156,550.00. Following the completion of the...
MarketBeat
Ligand Pharmaceuticals Incorporated $LGND Shares Sold by Kornitzer Capital Management Inc. KS
Kornitzer Capital Management Inc. KS lessened its stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 33.8% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 60,342 shares of the biotechnology compan...
MarketBeat
HC Wainwright Brokers Increase Earnings Estimates for LGND
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) - Stock analysts at HC Wainwright lifted their Q3 2026 earnings per share estimates for Ligand Pharmaceuticals in a research note...
MarketBeat
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Consensus Rating of "Moderate Buy" from Analysts
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Get Free Report) has earned an average rating of "Moderate Buy" from the eight brokerages that are currently covering the company, Marketbeat...
MarketBeat
HC Wainwright Issues Positive Forecast for Ligand Pharmaceuticals (NASDAQ:LGND) Stock Price
HC Wainwright boosted their target price on Ligand Pharmaceuticals from $243.00 to $289.00 and gave the company a "buy" rating in a research report on Thursday...
MarketBeat
Ligand Pharmaceuticals (NASDAQ:LGND) Shares Gap Down - Here's Why
Ligand Pharmaceuticals (NASDAQ:LGND) Shares Gap Down - What's Next...
MarketBeat
Moody Aldrich Partners LLC Has $3.70 Million Stock Holdings in Ligand Pharmaceuticals Incorporated $LGND
Moody Aldrich Partners LLC decreased its holdings in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 24.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 19,581 shares of the biotechnology company's stock after selling 6,303 sha...
MarketBeat
<
1
2
...
>